Drugs / EDB-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07461727 | Feb 2026 → Jan 2027 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDB-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07461727 ↗ |
| Action | Inhibit | “The drug is designed to specifically identify and disrupt the mutant EGFR-L858R gene in tumor cells, thereby inhibiting tumor growth.” NCT07461727 ↗ |
| Modality | CRISPR / gene editing | “EDB-102 utilizes the CRISPR-Cas9 gene-editing system delivered via lipid nanoparticles (LNPs).” NCT07461727 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous (IV) infusion of EDB-102.” NCT07461727 ↗ |
| Target | EGFR | “The drug is designed to specifically identify and disrupt the mutant EGFR-L858R gene in tumor cells, thereby inhibiting tumor growth.” NCT07461727 ↗ |